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Background/Purpose. Genetic variation in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene has been recently
identified as an important determinant of plasma LDL-cholesterol and severity of coronary heart disease. We studied whether
the PCSK9 gene is linked to the risk of ischemic stroke (IS) and with the development of intracranial atherosclerosis.Methods/
Results. The pivotal E670G polymorphism, tagging an important haplotype of the PCSK9 gene, was genotyped in two
independent studies. The Belgium Stroke Study included 237 middle aged (45–60) Belgian patients, with small-vessel occlusion
(SVO) and large-vessel atherosclerosis stroke (LVA), and 326 gender and ethnicity matched controls (.60 yrs) without a history
of stroke. In multivariate analysis the minor allele (G) carriers appeared as a significant predictor of LVA (OR=3.52, 95% CI
1.25–9.85; p = 0.017). In a Finnish crossectional population based consecutive autopsy series of 604 males and females (mean
age 62.5 years), G-allele carriers tended to have more severe allele copy number-dependent (p = 0.095) atherosclerosis in the
circle of Willis and in its branches. Conclusion. Our findings in this unique combination of clinical and autopsy data, provide
evidence that PCSK9 gene associates with the risk of LVA stroke subtype, and suggest that the risk is mediated by the severity
of intracranial atherosclerosis.
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INTRODUCTION
Familial predisposition has a modest effect (odds ratio (OR) 1.3–
1.76) to the risk of stroke in general [1]. Due to heterogeneity of
stroke, studies targeted on stroke subtypes could increase the
possibility to reveal underlying genetic background of stroke.
Earlier epidemiological studies have shown an increased genetic
influence in small-vessel occlusion (SVO) and large-vessel
atherosclerosis (LVA) stroke as defined by the Trial of org 10172
in acute treatment (TOAST) classification, particularly in relative
young stroke patients (OR 2.5–4.5, ,60 yrs) [2] [3] [4].
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine
protease, has recently gain a lot of attention because of its major
role in regulation of plasma low density lipoprotein (LDL)
cholesterol levels [5] [6] [7] [8] [9] [10] and in determining
coronary heart disease (CHD) risk [6] [11] [12]. PCSK9 promotes
degradation of the low density lipoprotein receptors (LDLR) in
liver through an unknown posttranscriptional mechanism [13] In
the large long-term Atherosclerosis Risk in Communities study,
some sequence variations of the PCSK9 gene associated both with
low LDL cholesterol levels and reduced incidence of coronary
events [6]. On the other hand, some other sequence variants have
associated with premature atherosclerosis development [12]. The
Lipoprotein Coronary Atherosclerosis Study (LCAS) investigators
identified the E670G variation as the most important tagging
polymorphism of the PCSK9 gene that acted as an independent
determinant of plasma LDL cholesterol levels and coronary
atherosclerosis severity [9]. Furthermore, the G allele has been
observed to relate to polygenic hypercholesterolemia in men [14].
In the present study we assessed the role of the E670G variation
tagging an important haplotype of the PCSK9 gene as a possible
risk factor for IS and its subtypes and we tested its association with
the semi quantitative score of atherosclerosis of the circle of Willis
and its branches in a large consecutive Finnish autopsy series.
MATERIALS AND METHODS
The Belgium Stroke Study (BSS) included 237 subjects with SVO
and LVA stroke according to the TOAST classification occurring
between 45 and 60 years of age. Among these patients 114 had
SVO, 103 LVA, and 20 had SVO and LAA. They were selected
from seven Stroke Units in Belgium. All patients were of central
European origin (.90% were Belgians). Gender and ethnicity
matched subjects (.60 years, n = 326) without a history of IS or
CHD were recruited as controls from the general population, in
order to avoid that the recruited controls would later turn out to be
actually cases, we on purpose selected older controls. The optimal
method of identifying and controlling for population stratification
in genetic association studies is not known. A recent study showed
that the grand parental country origin provided a better control
for stratification than the SNP based approach. [15] In this study,
the ethnicity was checked until the fourth grand parents.
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Cardiovascular risk factors (hypertension, diabetes mellitus,
hyperlipidemia, alcohol consumption (.2 glasses of alcohol
a day), smoking (former, current, never), obesity (body mass index
(BMI) .30)) were recorded in cases and controls. The study
protocol was approved by the ethical committees of all
participating Belgium hospitals: Erasme Hospital, CHU Brug-
mann, and Cliniques Universitaires Saint-Luc in Brussels, CHC
Clinique de l’Espe´rance of Montegne´, Cliniques Universitaires of
Mont-Godinne, CHU of Charleroi, and CHU of Tivoli. Informed
written consent was obtained from all patients before study entry.
The Tampere Coronary Study (TCS) is a cross-sectional
population based autopsy study comprising a total of 604 caucasian
Finnish autopsy cases who had died suddenly out-of-hospital. The
TCS included both men (64.3%, mean age 59.7) and women
(35.7%, mean age 68.2). In each case, the atherosclerosis of each of
the nine branches of the circle of Willis was scored semi-
quantitatively (0=normal, 1= slight: streaks with or without elevated
fibrous lesions, 2=moderate: fibrous lesions that cause ,50%
stenosis, 3= severe:.50 stenosis with extensive atherosclerosis (fatty,
fibrous, calcified lesions)) giving a range of scores from 0 to 27). The
study protocol was approved by the Board of Medicolegal Affairs of
Finland. Informed written consent was obtained from relatives.
Genotyping
In the BSS, DNA was isolated whole blood stored frozen at
220uC, with a commercial kit (Qiagen Inc. Valencia, CA)). In the
TCS, DNA isolation was performed from frozen blood samples
with the salt precipitation method. Genotyping was done by using
the 59 nuclease assay and fluorogenic allele-specific TaqMan MGB
probes in the ABI Prism 7900 HT sequence detection. The
nucleotide sequences of primers and probes used in the PCR of
E670G (23,968A.G) (rs 505151) were deduced from public
databases and synthesized in conjunction with Applied Biosystems.
Statistical analysis
The data was analyzed with the SPSS software (version 12.0, SPSS
Inc., Chicago, IL, USA).
The clinical data were compared between IS cases and controls,
using chi-square tests for discrete variable. Logistic regression
analysis with smoking, obesity, hypertension, alcohol consumption,
diabetes, and hyperlipidemia as dichotomous variables was used to
evaluate the association of E670G SNP with IS and its subtypes
(SVO and LVA). The association between E670G and intracranial
atherosclerosis was performed using a one-way ANOVA model,
followed by an ANCOVA analysis by adding gender as dichotomous
covariate and age, and BMI as continuous covariates in the model.
RESULTS
The clinical characteristic of cases and controls are presented in
Table 1. As expected the patients had a higher prevalence of
conventional cardiovascular risk factors than the controls (Table 1).
The genotype frequency distributions were in Hardy-Wein-
berg’s equilibrium among cases and controls. The frequency of
EE, EG and GG variants in the Belgium population were 94.1%
5.7% and 0.2%. Due to the rare occurrence of GG homozygotes,
G allele carriers (EG+GG) were combined and compared to EE
homozygotes. In a multivariate analysis the G allele tended to be
more common among IS cases than controls (8.1% vs. 4.3%;
p= 0.095). In particular, the G allele was significantly more
common among LVA patients than in control subjects (10.8% vs.
4.3%; p= 0.017 OR 3.52, 95%CI 1.25–9.85) (Table 2). With
a frequency of ,6% for the at risk allele at an alpha level of 0.05,
our sample was evaluated to have 80% power to detect a RR of
2.5 for heterozygote (‘‘genetic power calculator’’: http://statgen.
iop.kcl.ac.uk/gpc/cc2.html). The E670G variation was not related
to the risk of SVO (Table 2). As SVO and LVA were ad hoc
determined scientifically reasonable variables correction for
multiple testing was not primarily applied. However, Bonferoni
corrected p-values are also given in table 2 for LVA.
The frequency of EE, EG and GG variants in the Finnish
autopsy series was 86.4%, 12.4% and 1.3%. Compared to carriers
of the major EE genotype, G-allele carriers had more severe
atherosclerosis in the large intracranial cerebral arteries (EE= 4.71
(CI 4.17–5.26),G+=5.97 (CI 4.55–7.40) p = 0.095). There was
an allele copy number-dependent trend for the mean atheroscle-
rosis scores (EE= 4.71 (CI 4.17–5.26),EG=5.77 (CI 4.50–
7.25),GG=7.86 (CI 1.12–14.60); p = 0.169). (Figure 1)
Table 1. Clinical characteristics of stroke patients and controls.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Controls
n = 326 IS n = 237 p-value
Mean age (y) 70.3 53.5
Hypertension % 38.0 63.8 ,0.001
Diabetes % 10.8 16.3 0.042
Hyperlipemia % 36.5 57.9 ,0.001
Smoking status %
Current 9.3 55.9 ,0.001
Former 21.0 15.0
Never 69.8 29.1
Alcohol consumption (.2 glass/day) % 21.2 30.3 0.011
Familial history of MI or Stroke % 46.6 71.8 ,0.001
Obesity (BMI.30) % 13.2 16.5 0.172
Sex (male) % 66.0 66.8 0.856
x2 test
MI =myocardial infarction, BMI = body mass index
IS ischemic stroke
doi:10.1371/journal.pone.0001043.t001..
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Table 2. PCSK9 Genotype frequencies (%) for cases and controls.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PCSK9
genotype
Controls
N = 326
All IS
N = 237 p1 p2
OR
(95%CI)
LVA
N = 103 p1 p2 p3
OR
(95%CI)
SVO
N = 114 p1 p2
OR
(95%CI)
EE 95.7 91.9 0.047 0.095 2.10
(0.87-5.05)
89.2 0.019 0.017 0.034 3.52
(1.25-9.85)
93.8 0.286 0.699 1.23
(0.37-4.11)
EG + GG 4.3 8.1 10.8 6.2
Statistics: p1 = x 2 test, p2 = Logistic regression analysis, with adjustment for: hypertension, hyperlipemia, diabetes, obesity, smoking, alcohol consumption
LVA= large-vessel atherosclerosis, SVO= small-vessel occlusion, IS = ischemic stroke, p3 = after controlling for multiple testing with Bonferoni correction.
doi:10.1371/journal.pone.0001043.t002..
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DISCUSSION
The main observation of this study was that the E670G SNP of
PCSK9 gene associated significantly with LVA stroke risk in the
Belgian population. The same allele tended to associate with
increased atherosclerosis of the large intracerebral arteries in an
independent Finnish autopsy study, with a gene dose effect.
The PCSK9 gene encodes proprotein convertase subtilisin-
kexin type 9, a secreted enzyme of the serine protease family which
plays a role in regulating LDL receptor concentration in liver. Its
activation leads to decreased amounts of hepatic LDL receptors
and consequently to higher levels of plasma LDL cholesterol [16]
[17] [18]. Mutations in this gene have been associated with both
hypocholesterolemia and hypercholesterolemia through ‘‘loss-of-
function’’ [8] [19] [7] and ‘‘gain-of-function’’ [5] [20] [21] [12],
respectively. In addition, this gene has been suggested to be
involved in the risk for coronary heart disease [6] [11] [12], and to
contribute to the severity of coronary artery atherosclerosis in the
Lipoprotein Coronary Atherosclerosis Study (LCAS) study
population [9].
In this study, we have demonstrated a potential role of this gene
in cerebrovascular disease, especially in LVA stroke; which is
related to atherothrombotic lesions within large intracranial
arteries forming the circle of Willis in the brain base. This
observation is further supported by the fact that the same variant
tended to have a gene dose effect on atherosclerosis of the circle of
Willis arteries in the autopsy cases. However, this association was
not present with SVO which is caused predominantly by a diffuse
disease in smaller arterioles (lypohyalinose) and to a lesser extent
by atherosclerosis [22], Thus, PCSK9 seems to affect atheroscle-
rosis development similarly in different vascular beds of similar
calibre and determine Cerebrovascular LVA as well as CHD
events.
The mechanism by which PCSK9 affects this phenotype could
be related to its known effect on plasma LDL-cholesterol
concentrations. It is also possible that PCSK9 itself may have
a direct pro-atherogenic effect. This was suggested by Cohen et al
(7), as they observed that protection against coronary heart disease
risk was greater than expected by the effect of PCSK9 sequence
variants on LDL cholesterol [6].
In conclusion, we found that the pivotal E670G polymorphism,
tagging an important haplotype of the PCSK9 gene associates
specifically with the risk of LVA stroke subtype, and tended to
have a gene dose effect on the severity of atherosclerosis of the
large intracranial arteries forming the circle of Willis. Based on
earlier observations on the major effect of sequence variation of
PCSK9 gene on plasma LDL cholesterol concentrations and
coronary heart disease risk and the result of the current study,
PCSK9 seems to be an interesting new target molecule for the
development of new antiatherogenic therapies.
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